[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][Branch1][C][C][C][C@@H1][Branch2][Ring1][S][C][=Branch1][C][=O][N][C@@H1][Branch1][#Branch2][C][C@@H1][C][C][N][C][Ring1][Branch1][=O][C][=Branch1][C][=O][C][O][P][=Branch1][C][=O][Branch1][C][O][O][N][C][=Branch1][C][=O][C][=C][C][=C][Branch1][Ring2][N][Ring1][Branch1][C][=C][C][=C][Ring1][#Branch1][O][C]"}, {"from": "gpt", "value": "The molecule is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply. Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects. PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was subsequently shelved as the outbreak was controlled. Now, it is being tested regarding the novel SARS-CoV-2 virus, including studies in conjunction with [Remdesivir] to treat COVID-19 infection; in vitro data showed synergistic effects on articles published on preprint servers. Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167)."}]